Bioventus (BVS) Q1 2025 Earnings
How Did BVS Stock React to Q1 2025 Earnings?
S&P 500 over the same 30 days: +7.22%.
Did BVS Beat Earnings? Q1 2025 Results
Yes. Bioventus reported Q1 2025 earnings of $0.08 a share on May 6, 2025, beating the $0.02 consensus estimate by 250.9%. Revenue was $123.9M against a $122.7M estimate.
Bioventus delivered a sharply better-than-expected first quarter, posting non-GAAP EPS of $0.08 against a consensus estimate of $0.02, a beat of 250.88%, while revenue of $123.88 million edged past the $122.71 million consensus by 0.95%. Reported revenue fell 4.3% year over year, a decline tied almost entirely to the company's divestiture of its Advanced Rehabilitation Business at the end of 2024; strip out that transaction and organic revenue grew 5.0%, with all three business segments contributing positively. Pain Treatments, the largest segment at $58.92 million, benefited from double-digit demand growth for Durolane, its single-injection knee osteoarthritis therapy, while Surgical Solutions added 7.0% growth to $45.23 million on strong Ultrasonics capital equipment sales. The net loss attributable to Bioventus narrowed to $2.64 million from $4.89 million a year ago, and interest expense fell to $7.51 million from $10.34 million as debt reduction efforts gained traction. Management reiterated full-year 2025 guidance calling for net sales of $560 million to $570 million and non-GAAP EPS of $0.64 to $0.68, representing growth of 30.6% to 38.8%.
- Double-digit growth in demand for Durolane single-injection HA therapy for knee osteoarthritis
- Double-digit growth from Ultrasonics driven by strong U.S. capital equipment purchases
- Organic revenue growth of 4.0% in Restorative Therapies driven by improved commercial effectiveness with EXOGEN
- Interest expense reduction to $7.5 million from $10.3 million year-over-year
“Our Bioventus team delivered solid results to start the year and we are making substantial progress with executing our strategic plan.”
Bioventus CEO, on the earnings call
What Was Bioventus's Outlook in Q1 2025?
Bioventus reiterated its full-year 2025 guidance, which now includes an estimated immaterial impact from tariffs. The company expects net sales of $560 million to $570 million, reflecting organic growth of approximately 6.1% to 8.0% when including the impact of the Advanced Rehabilitation Business divestiture (which generated $45.4 million in 2024). Adjusted EBITDA is expected to be $112 million to $116 million, reflecting 100 basis points of margin growth compared to 2024's 19.0% Adjusted EBITDA Margin. Non-GAAP EPS is expected to be $0.64 to $0.68, representing an increase of 30.6% to 38.8%.
BVS YoY Financials
| Metric | Q1 2025 | Q1 2024 | Year over year |
|---|---|---|---|
| Revenue | $123.9M | $129.5M | −4.3% |
| Gross Profit | $83.1M | $88.4M | −6.0% |
| Operating Income | $4.9M | $4.9M | −1.2% |
| Net Income | −$3.3M | −$2.5M | +32.1% |
BVS Revenue by Segment
BVS Revenue by Geography
Figures from SEC filings and company reports. Not investment advice.